文献速递泌尿男性生殖肿瘤

转移性去势抵抗性前列腺癌患者中奥拉帕利的耐受性与常见不良事件管理:PROfound研究的进一步分析

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
PubMed 文献 · Eur J Cancer · 2022-05-19

基于PROfound研究,奥拉帕利获批用于既往至少接受恩扎卢胺或阿比特龙治疗后进展且携带DNA修复基因相关变异的转移性去势抵抗性前列腺癌患者。本文进一步报告PROfound的安全性数据,聚焦四种最常见不良事件及特别关注事件。奥拉帕利组与对照组分别为256例和130例,最常见不良事件为贫血50%、恶心43%、乏力/虚弱42%、食欲下降31%,多为1-2级并在治疗前2个月内达峰,经剂量中断或剂量减少等管理后通常无需停药。

要点

  • 奥拉帕利组四种最常见不良事件(全因)为贫血50%、恶心43%、乏力/虚弱42%、食欲下降31%。
  • 上述事件多为1-2级,均在治疗前2个月内达峰,主要经剂量中断或剂量减少管理。
  • 奥拉帕利组与对照组肺炎分别为2%与1.5%,静脉血栓栓塞事件分别为8%与3%。

核心结论

  • PROfound研究中奥拉帕利四种最常见不良事件通常可管理,无需停止治疗,使患者能在获得临床获益期间持续治疗。

研究设计与样本

  • PROfound研究的进一步安全性分析,患者按2:1随机接受奥拉帕利片剂300 mg每日两次或对照组(恩扎卢胺或阿比特龙),治疗至疾病进展或不可接受毒性。
  • 奥拉帕利组256例,对照组130例;安全性通过不良事件报告和实验室评估进行评价。
  • 对照组中发生影像学疾病进展后交叉接受奥拉帕利治疗的所有患者也收集了安全性数据。

主要发现

  • 奥拉帕利组四种最常见不良事件(全因)发生率:贫血50%、恶心43%、乏力/虚弱42%、食欲下降31%。
  • 上述不良事件大多为1级和2级,均在治疗前2个月内达峰,并酌情主要经剂量中断或剂量减少进行管理。
  • 基线骨转移范围或既往紫杉烷使用与贫血发生率无关。
  • 肺炎在奥拉帕利组和对照组分别报告于2%和1.5%的患者;奥拉帕利组1例患者(0.4%)在30天随访期后发生MDS/AML事件。
  • 静脉血栓栓塞事件发生于奥拉帕利组8%和对照组3%的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest. METHODS: Patients were randomized (2:1) to olaparib tablets (300 mg bid) or control (enzalutamide or abiraterone) until disease progression or unacceptable toxicity. Safety was assessed through AE reporting and laboratory assessments. Safety data were also collected from all patients in the control group who experienced radiographic disease progression and subsequently crossed over to olaparib treatment. RESULTS: 256 patients received olaparib and 130 control. Incidence rates for the four most commonly occurring AEs in the olaparib group (all-causality) were anaemia 50%, nausea 43%, fatigue/asthenia 42% and decreased appetite 31%. All were mostly Grade 1 and 2 and all peaked within the first 2 months of treatment as the events were managed where appropriate, primarily with dose interruptions or dose reductions. The extent of bone metastases at baseline or prior taxane use was not associated with the rate of anaemia. Pneumonitis was reported in 2% and 1.5% of patients in the olaparib and control groups, respectively, and one patient (0.4%) in the olaparib group experienced an event of MDS/AML after a 30-day follow-up period. Venous thromboembolic events occurred in 8% of olaparib and 3% of control patients. CONCLUSIONS: The four most common AEs observed in PROfound were generally manageable without the need for treatment discontinuation, allowing patients to remain on treatment for as long as they were deriving clinical benefit. CLINICALTRIALS: gov registration number: NCT02987543.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Roubaud G, Özgüroğlu M, Penel N, et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. Eur J Cancer. 2022. PMID: 35598359. doi:10.1016/j.ejca.2022.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。